Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Quest Diagnostics Nichols Institute
EIR
•Quest Diagnostics Nichols Institute•September 23, 2019

Quest Diagnostics Nichols Institute – FDA EIR, Sep 23, 2019

Record Details

An FDA inspection of Quest Diagnostics Nichols Institute in Chantilly, VA, was conducted from September 9 to September 23, 2019. The inspection covered their operations as a CLIA-certified and FDA-registered donor testing laboratory for living human cells, tissues, and cellular and tissue-based products (HCT/P) and blood donors. This comprehensive review, part of the Office of Biological Products Operations Division's work plan, assessed the Quality Assurance System and Product Testing System, adhering to established FDA compliance programs for blood banks and HCT/P inspections.

The inspection identified several significant issues, leading to the issuance of a Form FDA-483, "Inspectional Observations," to the Medical Director. A primary concern was that communicable disease testing, specifically for HIV-1/HCV/HBV NAT, was not performed according to manufacturer instructions. The company's practice of reporting non-discriminated test results with insufficient sample as "TEST ORDER CANCELED" deviated from the manufacturer's requirement to report them as "non-discriminated."

Furthermore, the quality program was found inadequate in maintaining and following appropriate procedures related to current good tissue practice requirements. This included an SOP for HIV-1/HCV/HBV NAT testing that did not align with manufacturer guidelines, and another SOP for HIV antibody screening that failed to exclude specimens subjected to more than four freeze-thaw cycles, a limitation specified by the manufacturer. Management also failed to adequately document manual temperatures during refrigeration unit excursions.

In response, Quest Diagnostics Nichols Institute's management acknowledged the observations and committed to submitting a written response to the FDA within 15 business days. They also agreed to expand a deviation report to cover all impacted specimens since the relevant SOP's inception in 2010 and improve documentation practices for temperature monitoring.

Company
Quest Diagnostics Nichols Institute
Inspection date
September 23, 2019
Product type
biologics
Office
Baltimore District Office
People
  • Shavon L. Square (issuing_officer)
  • Amanda B. Athey
View Company Profile

ID · 282f78be-80fd-4cb9-90c3-72b4a229dc5e

Violation Codes2
21 CFR 1271.80(c)21 CFR 1271.160(b)(1)

Full citation text and observation details available on the Dashboard.

Other documents for Quest Diagnostics Nichols Institute
  • 483 - 2021-08-30August 30, 2021
  • 483 - 2019-09-23September 23, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Quest Diagnostics Nichols Institute
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.